Comparative study of the metabolic and anthropometric profile of patients with polycystic ovary syndrome under treatment with oral contraceptives containing drospirenone or cyproterone

• Autor(a) principal: Araujo, Beatriz Mendes de
• Data de Publicação: 2021
• Outros Autores: Albuquerque, Morgana Pinheiro, Lopes, Ione Maria Ribeiro Soares
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Research, Society and Development
• Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/18983
• topic: Síndrome dos ovários policísticos; Síndrome metabólica; Anticoncepcional oral.; Síndrome de ovario poliquístico; Síndrome metabólico; Anticonceptivo oral.; Polycystic ovary syndrome; Metabolic syndrome; Oral contraceptive.

Polycystic Ovary Syndrome (PCOS) is a heterogeneous endocrine dysfunction characterized by oligoamenorrhea and hyperandrogenism. It is associated with comorbidities such as insulin resistance, hyperlipidemia, cardiovascular diseases, cosmetic problems and infertility.  Analyse and compare possible impacts on the anthropometric, metabolic and cardiovascular profiles of patients with PCOS before and after 06 months of treatment with combined oral contraceptives (COC) containing Ethinylestradiol (EE) 0.035mg + Cyproterone 2mg or EE 0.03mg + Drospirenone 3mg. Observational, prospective and analytical study, with quantitative approach, approved by the REC of HU-UFPI (number 2.568.977), accomplished between August 2018-June 2019. Women aged 18 to 40 years with a confirmed diagnosis for PCOS were selected and divided into two homogeneous groups to use the following combinations for 06 months: Group 1 (EE + Cyproterone) and Group 2 (EE + Drospirenone). Statistical t-Student and Mann-Whitney U tests were used for data analysis, with a 5% significance level.  Anthropometric and metabolic data of the 16 selected participants were analyzed before and after 6 months of COC therapy. There was a statistically significant reduction in BMI in group 2 and a significant increase in HDL and Total Cholesterol in group 1.  After 06 months of using these COCs, it was observed: improvement in Total Cholesterol and HDL with EE + Cyproterone; reduction in BMI with EE + Drospirenone; absence of additional risk in the metabolic, anthropometric and cardiovascular profile; no clinical superiority in the metabolic risk of one hormonal combination over the other in patients with PCOS.